Targeting complement in ANCA-associated vasculitis: insights from ADVOCATE

Glucocorticoids have, for decades, been an enduring component of treatment regimens for anti-neutrophil cytoplasm autoantibody (ANCA)-associated vasculitis. However, a growing number of studies have encouraged a move towards reduced glucocorticoid usage. Findings of the ADVOCATE trial suggest that c...

Full description

Saved in:
Bibliographic Details
Published in:Nature reviews. Nephrology 2021-07, Vol.17 (7), p.439-440
Main Authors: Prendecki, Maria, McAdoo, Stephen P.
Format: Article
Language:English
Subjects:
692/4022/1585/2759
692/4023/1670/595
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis - drug therapy
Autoantibodies
Causes of
Complement System Proteins
Corticosteroids
Cytoplasm
Dendritic cells
Disease
Dosage and administration
Drug therapy
Humans
Infections
Inflammation
Medicine
Medicine & Public Health
Nephrology
Neutrophils
News & Views
news-and-views
Physiological aspects
Vasculitis
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Glucocorticoids have, for decades, been an enduring component of treatment regimens for anti-neutrophil cytoplasm autoantibody (ANCA)-associated vasculitis. However, a growing number of studies have encouraged a move towards reduced glucocorticoid usage. Findings of the ADVOCATE trial suggest that complement blockade may pave the way for complete glucocorticoid avoidance.
ISSN:1759-5061
1759-507X
DOI:10.1038/s41581-021-00417-3